A neurosurgeon and his team from the University of California (UC) Davis Health have won The Herbert Pardes Clinical Research Excellence Award — given by the nonprofit Clinical Research Forum — for their work on a brain-computer interface that translates brain signals into speech with greater than 95% accuracy.
Brain-computer interface to restore speech named award winner
Sometime in my mid-40s, I wrote a list of goals I wanted to achieve before turning 50. I no longer have the list, but I remember a few things on it: Learn a second language. Complete one half-marathon each year. And my then-favorite, visit 50 countries by the time I…
Treatment with regulatory T-cells, or Tregs — a type of anti-inflammatory immune cell — was well tolerated and seemed to slow disease progression in a small clinical trial that enrolled six people with amyotrophic lateral sclerosis (ALS). The work was conducted by scientists at Columbia University in New…
Signs of spring appear every day outside my kitchen window here in northern Michigan, even as my own life feels heavy with my care for my husband, Todd, who has ALS. After a long winter, our 2 feet of snow, which was in the field behind our house a…
The U.S. Food and Drug Administration (FDA) has given Xellsmart Biopharmaceutical the go-ahead to start a Phase 1 clinical trial testing its stem cell-based therapy XS-228 in people with amyotrophic lateral sclerosis (ALS). This milestone, reflecting the approval of Xellsmart’s investigational new drug (IND) application, follows promising results…
Some days, my motivation just gets stuck. Even though I’ve got interesting plans and projects to do, I can’t get started on any of them. The reasons why can include not getting enough hours of sleep the night before, being caught up in the latest news cycle, or simply reflecting…
A combination of three drugs — one of them the experimental therapy CuATSM — may be effective for treating amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, according to a new preclinical study. In mice carrying SOD1 mutations, the combination of these three drugs — CuATSM,…
RNS60 was well tolerated when inhaled twice daily at home as part of an expanded access program (EAP), and it could be a safe option for people with advanced amyotrophic lateral sclerosis (ALS), a study suggested. “This EAP supports the safety and tolerability of RNS60,” researchers wrote in “…
The first patient has been dosed in a Phase 1 clinical study testing AMX0114, an experimental therapy being developed by Almylyx Pharmaceuticals for amyotrophic lateral sclerosis (ALS). The treatment targets calpain-2, a protein believed to contribute to nerve cell damage in ALS. Called LUMINA (NCT06665165), the study was cleared…
The first patient has been enrolled in an expanded access program (EAP) trial evaluating MN-166 (ibudilast), Medicinova’s oral anti-inflammatory drug, in people with amyotrophic lateral sclerosis (ALS). EAPs, also known as compassionate use programs, allow patients with serious or life-threatening conditions to access investigational therapies outside of clinical…
Recent Posts
- New funding backs commercial readiness efforts for ALS therapy
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients